NENdidi Atasie Eboh

Ndidi Atasie Eboh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ndidi Atasie Eboh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Artificial Intelligence in Surgery: Current Applications and Future Prospects

    by Peter Aduvie Josiah, Chinedu Nwosu-Ijiomah, Ndidi Atasie Eboh

    Artificial intelligence (AI) is transforming the practice of surgery through the support of clinical decision-making, improved accuracy and efficiency, and better patient outcomes across the perioperative period. This review evaluates and critically analyzes current, technological and evidence-based applications of AI in surgery. Machine learning, deep learning, computer vision and natural language processing are some of the core AI technologies that are enabling developments in all phases of surgery. Some of these applications include, improved preoperative diagnosis, intraoperative real-time imaging, workflow analysis, robotic surgery assistance and intraoperative clinical decision support. Postoperatively, the potential of AI is also vast. Through the use of predictive models for surveillance and early complications detection, as well as remote management of patients, AI is optimizing postoperative care. Although the findings suggest promise for the future, the clinical adoption of AI in surgery is limited by a number of issues, including data quality and heterogeneity, lack of validation in large prospective studies, potential for bias, ethical concerns and high costs of implementation. Other factors including clinician acceptance, data privacy, regulatory approval and medico-legal implications need to be addressed before any new technology is widely adopted. Future directions of AI in surgery includes progression to semi-autonomous systems that augments the efforts of the surgeon, integration with emerging technologies such as genomics and digital twins, and increased use in low resource settings to help address existing global inequities in surgical care. For successful AI adoption in surgery, AI systems will need to undergo robust validation, require interdisciplinary approaches, and all systems must be developed in a manner that is not only transparent but also clinically appropriate for surgeons, so that it can maximise the benefits of human talent in the operating room while maintaining patient safety.

  • Advancements in Minimally Invasive Surgery: From Laparoscopy to Robotic Precision

    by Peter Aduvie Josiah, Chinedu Nwosu-Ijiomah, Ndidi Atasie Eboh

    Minimally invasive surgery (MIS) has become a dominant surgical paradigm over the last two decades due to its benefits such as less tissue trauma and shorter convalescence for patients. This narrative review presents the progress in MIS from conventional laparoscopic to robotic surgical interventions, highlighting advancements in technology, clinical and educational applications. Early advances in fiber-optic imaging, video-laparoscopy, and creation of corresponding surgical instruments enabled the transition from a purely diagnostic to therapeutic MIS approach and facilitated surgical innovation among many specialties. However, conventional laparoscopy is constrained by several factors, including rigidity of surgical instruments, two-dimensional imaging, and surgical ergonomics. Recent advances in robotic-assisted surgery have sought to address several of these limitations by providing surgeons with greater dexterity, tremor filtering, motion scaling, improved three-dimensional visualization and enhanced intra-abdominal working space. Early clinical results are promising with evidence suggesting reduced postoperative morbidity in selected complex procedures, although outcomes for robotic and conventional laparoscopic approaches remain comparable for many standard operations. Moreover, MIS is influencing surgical training through the use of surgical simulation models, structured credentialing and performance-based skill assessments. Although much has been achieved with MIS, there are barriers to its widespread adoption, namely cost and access in less well-resourced surgical environments, as well as concerns relating to equity, accountability and informed patient consent. Moving forward, incorporating emerging technologies such as artificial intelligence, augmented reality and semi-autonomous systems will be pivotal to optimizing MIS. The future of MIS lies in the provision of personalized surgical care as part of an overall vision for precision surgery.

  • Use of Artificial Intelligence and Machine Learning in Rapid Drug Discovery and Pharmacovigilance

    by Ogboh Rita Onyebuchi, Olukunle O. Akanbi, Adepeju Kafayat Olowookere, Isaac Baiden, Faith Chinaza Ngwoke, Onodje Lucky, Akinlolu Oluwamisimi, Ndidi Atasie Eboh, Uchechukwu Lilian Okoye

    The increasing global burden of disease, rising research and development costs, and high attrition rates in pharmaceutical pipelines underscore the need for more efficient approaches to therapeutic development and drug safety monitoring. Artificial intelligence (AI) and machine learning (ML) have emerged as data-driven tools with the potential to improve multiple stages of the pharmaceutical lifecycle. This narrative review is designed to provide a structured and critical overview of the use of AI and ML in drug discovery and drug safety surveillance. A comprehensive literature search was performed to identify relevant studies using major electronic databases, with emphasis on publications from 1997 to March 2025. The studies were selected based on the inclusion criteria. The findings of the study show that AI and ML are being used in drug discovery, drug development, and drug safety surveillance. These technologies have the potential to provide predictive models, integrate heterogeneous biomedical data, and analyze real-world data to detect adverse drug reactions. Deep learning and natural language processing have been found to be useful tools to improve early risk detection. However, some limitations have also been found. These include the quality of the data, bias in AI and ML models, lack of interpretability of AI and ML models, lack of external validation, and lack of real-world implementation. These limitations need to be addressed to make AI and ML more useful tools for drug discovery and drug safety surveillance. Overall, while AI and ML offer meaningful opportunities to enhance drug discovery and pharmacovigilance, their impact remains dependent on rigorous validation, improved data governance, and alignment with clinical and regulatory frameworks. Continued research and context-specific implementation strategies will be essential to support their effective and equitable integration into pharmaceutical research and healthcare systems.

  • Integrating Social Determinants of Health into Precision Medicine: A Critical Review of a Missing Link in Personalized Healthcare

    by Daniel Obinna Eke, Chidinma Lorretta Gab-Obinna, Victor Ibiam, Isaac Baiden, Akinlolu Oluwamisimi, Ndidi Atasie Eboh

    Background: Precision medicine has transformed healthcare through advances in genomics, biomarkers, and artificial intelligence. However, its predominant focus on biological determinants reflects a reductionist approach that inadequately captures the broader social and environmental factors influencing health outcomes. Aim: This review aims to critically examine the limitations of current precision medicine frameworks, particularly the exclusion of social determinants of health (SDOH), and to explore the need for a more integrative, context-aware approach to personalized healthcare. Methods: A critical narrative review was conducted using literature from PubMed, Scopus, and Web of Science, covering publications between 2015 and 2025. Relevant studies addressing precision medicine, SDOH, health disparities, and artificial intelligence were selected based on predefined inclusion criteria and analyzed using thematic synthesis. Results: The findings reveal that current precision medicine models are constrained by biological reductionism, data bias, algorithmic inequities, and fragmented data systems. The exclusion of SDOH limits predictive accuracy, reduces the effectiveness of personalized interventions, and contributes to persistent health disparities. Emerging evidence highlights the potential of integrating artificial intelligence and digital health technologies with social and behavioral data to enhance context-aware care. Conclusion: Precision medicine, as currently practiced, is biologically precise but contextually incomplete. Integrating SDOH into precision medicine frameworks is essential for improving clinical effectiveness, promoting health equity, and ensuring real-world applicability. A shift toward an integrative model that combines biological, social, and behavioral determinants is necessary to achieve truly personalized and patient-centered healthcare.